Forsta AP Fonden Buys 800 Shares of Moderna, Inc. (NASDAQ:MRNA)

Forsta AP Fonden grew its stake in shares of Moderna, Inc. (NASDAQ:MRNAGet Rating) by 1.0% during the first quarter, Holdings Channel reports. The institutional investor owned 82,900 shares of the company’s stock after purchasing an additional 800 shares during the quarter. Forsta AP Fonden’s holdings in Moderna were worth $14,280,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of Moderna by 2.9% during the fourth quarter. BlackRock Inc. now owns 27,661,473 shares of the company’s stock valued at $7,025,462,000 after buying an additional 772,313 shares during the last quarter. State Street Corp grew its stake in shares of Moderna by 6.5% in the fourth quarter. State Street Corp now owns 14,863,370 shares of the company’s stock worth $3,774,999,000 after purchasing an additional 905,789 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Moderna by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 6,032,463 shares of the company’s stock worth $1,527,786,000 after purchasing an additional 272,502 shares during the last quarter. Theleme Partners LLP grew its stake in shares of Moderna by 26.9% in the fourth quarter. Theleme Partners LLP now owns 5,022,174 shares of the company’s stock worth $1,275,532,000 after purchasing an additional 1,065,100 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Moderna by 0.7% in the fourth quarter. Northern Trust Corp now owns 3,482,909 shares of the company’s stock worth $884,589,000 after purchasing an additional 23,555 shares during the last quarter. 61.20% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Stephane Bancel sold 40,000 shares of Moderna stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $192.94, for a total transaction of $7,717,600.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $1,044,180,861.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Juan Andres sold 195 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $133.71, for a total value of $26,073.45. Following the completion of the transaction, the insider now directly owns 9,309 shares in the company, valued at approximately $1,244,706.39. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $192.94, for a total transaction of $7,717,600.00. Following the completion of the transaction, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at $1,044,180,861.24. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 606,029 shares of company stock worth $91,997,025. Insiders own 17.30% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on MRNA shares. SVB Leerink raised their target price on Moderna from $70.00 to $77.00 and gave the stock an “underperform” rating in a research note on Monday, August 1st. Morgan Stanley cut their target price on Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research note on Thursday. Finally, Piper Sandler cut their target price on Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $226.92.

Moderna Stock Performance

Moderna stock opened at $186.84 on Friday. The stock’s 50 day simple moving average is $152.33 and its two-hundred day simple moving average is $152.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.99. The stock has a market cap of $74.32 billion, a price-to-earnings ratio of 5.69, a PEG ratio of 1.09 and a beta of 1.61. Moderna, Inc. has a fifty-two week low of $115.61 and a fifty-two week high of $497.49.

Moderna (NASDAQ:MRNAGet Rating) last released its earnings results on Wednesday, August 3rd. The company reported $5.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.73 by $0.51. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The firm had revenue of $4.73 billion during the quarter, compared to analyst estimates of $3.95 billion. During the same period last year, the business earned $6.46 earnings per share. The business’s revenue was up 8.7% on a year-over-year basis. As a group, analysts expect that Moderna, Inc. will post 27.35 earnings per share for the current fiscal year.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Featured Articles

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNAGet Rating).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.